S-1/A: Palisade Bio Files Amendment for $5.75 Million Public Offering to Fund Clinical Trials

Palisade Bio has filed an amendment to its registration statement for a public offering of common stock and pre-funded warrants, aiming to raise up to $5.75 million to support its clinical development programs.

Summary

• Palisade Bio is seeking to raise capital through a public offering of 2,057,613 shares of common stock, or pre-funded warrants, at an assumed price of $2.43 per share.
• The company is also offering representative warrants to the underwriters, exercisable for up to 123,456 shares of common stock.
• The offering includes an over-allotment option for underwriters to purchase an additional 308,641 shares.
• The primary use of proceeds will be to fund the Phase 1 clinical trial of PALI-2108, pre-clinical studies, research and development, and working capital.
• The company's lead product candidate, PALI-2108, is being developed for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
• Palisade Bio has commenced a Phase 1 clinical trial in Canada and plans to file an Investigational New Drug Application with the FDA in 2025.
• The company estimates the net proceeds from the offering to be approximately $4.18 million, or $4.87 million if the over-allotment option is fully exercised.

Sentiment

Score: 6

Explanation: The document presents a mix of positive developments, such as the commencement of a Phase 1 trial and a clear plan for future clinical development, alongside significant risks and financial uncertainties, including a going concern qualification and a history of losses. The sentiment is cautiously optimistic, reflecting the potential of the company's technology but also the challenges it faces.

Positives

• The company has commenced a Phase 1 clinical trial for PALI-2108 in Canada, marking a significant step in its development.
• Palisade Bio has a biomarker-based patient selection approach that may improve clinical response rates.
• The company has a license agreement with Giiant Pharma, providing rights to develop and commercialize compounds related to PALI-2108.
• The company has identified a large addressable patient population for PALI-2108 in the US and EU, estimated at approximately 205,000 per year.
• The company has a clear plan to use the proceeds from the offering to advance its clinical programs.

Negatives

• The company has a limited operating history and has never generated revenue from product sales.
• The company has expressed substantial doubt about its ability to continue as a going concern.
• The company has a history of net operating losses and expects to continue to incur losses.
• The company has identified a material weakness in its internal controls over financial reporting.
• The company is dependent on third parties for clinical trials, manufacturing, and supply of drug substances.
• The company's stock price may be highly volatile.

Risks

• The company's business depends on the successful clinical development, regulatory approval, and commercialization of PALI-2108.
• There are substantial risks in drug development, and the company may not be able to successfully develop PALI-2108.
• The company depends on its license agreement with Giiant, and termination of this agreement could harm the business.
• Even if clinical trials in Canada are successful, obtaining regulatory approval in the United States is uncertain.
• The company may find it difficult to enroll patients in clinical trials, which could delay or prevent progress.
• The company expects that its operations and development of PALI-2108 will require substantially more capital than it currently has.
• The company's product candidates may cause undesirable side effects or have other unexpected properties.
• There can be no assurance that the company's product candidates will obtain regulatory approval.
• The company is conducting a Phase 1 clinical trial of PALI-2108 in Canada, and the FDA may not accept data from such trials.
• The company's common stock could be delisted from the Nasdaq Stock Market if it is unable to maintain compliance with listing standards.

Future Outlook

The company anticipates filing an Investigational New Drug Application (IND) with the United States Food and Drug Administration (FDA) during 2025 and commencing clinical trials of PALI-2108 in the United States during the second half of 2025. Topline data from the Phase 1 study is expected in the second quarter of 2025.

Industry Context

The document highlights the increasing prevalence of inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, and the growing market for treatments, indicating a significant opportunity for Palisade Bio's PALI-2108 if it is successfully developed and approved.

Comparison to Industry Standards

• The document mentions the market size for UC and CD treatments, which are comparable to other companies in the space, such as AbbVie (Humira, Rinvoq), Takeda (Entyvio), and Johnson & Johnson (Stelara).
• The company's approach of using a prodrug inhibitor with localized bioactivation in the colon is a unique approach compared to systemic treatments offered by competitors.
• The company's biomarker-based patient selection approach is also a differentiating factor, aiming to improve clinical response rates compared to standard treatments.

Related Party Transactions

• The document details several related party transactions, including issuances of securities and warrants to Altium Growth Fund, LP and Yuma Regional Medical Center, both of which are significant shareholders.
• It also mentions compensation arrangements with directors and executive officers, including stock options and restricted stock units.

Stakeholder Impact

• Shareholders will experience dilution due to the public offering.
• Employees may benefit from the company's growth and development.
• Patients with IBD may benefit from the development of PALI-2108 if it is successful.
• Creditors and suppliers may be impacted by the company's financial performance and ability to continue as a going concern.

Next Steps

• File an Investigational New Drug Application (IND) with the FDA in 2025.
• Commence clinical trials of PALI-2108 in the United States during the second half of 2025.
• Announce topline data from the Phase 1 study in the second quarter of 2025.
• Initiate a Phase 1b/2a clinical study in UC patients in the second half of 2025.

Key Dates

Keywords

Palisade Bio, PALI-2108, Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease, Clinical Trial, Public Offering, Pre-funded Warrants, Biopharmaceutical, PDE4 Inhibitor